enGene Holdings Inc. (ENGN) Stock Score, Valuation & Financial Research

enGene Holdings Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ENGN

enGene Holdings Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.80. These figures are a research snapshot, not a buy or sell recommendation.

What enGene Holdings Inc. does

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Company business and revenue

Research reporting period: 2025-10-31. A research update is not a new financial filing.

How the company makes money

enGene is a clinical-stage biotechnology company that focuses on the research, discovery, and clinical development of genetic medicines. The company does not currently generate revenue from product sales and relies on capital raises and debt facilities to fund its operations and the development of its proprietary non-viral gene therapy platform.

Products and services

  • The company's lead product candidate is detalimogene voraplasmid (detalimogene), a non-viral gene therapy designed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) using a proprietary DDX delivery vehicle.

Brands and product families

  • detalimogene voraplasmid — Lead product candidate for the treatment of NMIBC. Source

Customer types

Patients with Non-Muscle Invasive Bladder Cancer.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug product candidates. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing gene therapies and treatments for bladder cancer, including those utilizing viral and non-viral delivery platforms. Source

Business strengths to evaluate

  • Proprietary DDX delivery vehicle technology Source
  • Patent-protected manufacturing processes Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate Source
  • Reliance on third-party manufacturers and suppliers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ENGN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.80
Market capitalization:
120.58M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -4.9M
Free cash flow:
USD -100.72M
Cash:
USD 41.03M
Total debt:
USD 33.27M
EPS:
USD -0.28

What stands out

  • Free cash flow is USD -100.72M, negative for the stored period.
  • The balance sheet shows USD 41.03M of cash versus USD 33.27M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.75M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ENGN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ENGN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does ENGN's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for ENGN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ENGN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ENGN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.